{"filing":{"accession_number":"0001193125-26-290473","cik":"0001671584","ticker":"APVO","company_name":"Aptevo Therapeutics Inc.","form":"8-K","filing_date":"2026-06-30","report_date":null,"primary_document":"apvo-20260629.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526290473/apvo-20260629.htm"},"events":[{"id":15038,"run_id":13418,"accession_number":"0001193125-26-290473","anchor_item_number":"1.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Aptevo entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund for $1.5 million in non-dilutive research funding to support IND-enabling studies for APVO451, a trispecific antibody candidate. This material research partnership provides external validation and advances a strategic pipeline priority toward clinical development.","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-06-30","form":"8-K","submitted_at":null,"items":[{"id":12655,"accession_number":"0001193125-26-290473","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund for $1.5 million in non-dilutive research funding to support IND-enabling studies for APVO451, a trispecific antibody candidate. This is a material research partnership and funding arrangement that advances a strategic pipeline priority, but it does not fit the specific categories of debt issuance, equity dilution, M\u0026A activity, or other named event types. The grant is operational in nature—supporting preclinical development and IND-enabling work—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:21:15.748554+00:00","company_name":"","ticker":null,"filing_date":""},{"id":12656,"accession_number":"0001193125-26-290473","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced receipt of a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, a trispecific immunotherapy candidate. This is a material operational and strategic milestone—the grant provides external validation of the program, funds advancement toward development candidate selection and IND-enabling studies, and reflects progress on a stated strategic pipeline priority. While not a traditional M\u0026A, financing, or governance event, the grant materially advances the company's clinical development timeline and demonstrates external recognition of its scientific approach, making it operationally significant to investors assessing pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:21:15.748554+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":12655,"accession_number":"0001193125-26-290473","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund for $1.5 million in non-dilutive research funding to support IND-enabling studies for APVO451, a trispecific antibody candidate. This is a material research partnership and funding arrangement that advances a strategic pipeline priority, but it does not fit the specific categories of debt issuance, equity dilution, M\u0026A activity, or other named event types. The grant is operational in nature—supporting preclinical development and IND-enabling work—making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:21:15.748554+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-06-30"},{"id":12656,"accession_number":"0001193125-26-290473","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Aptevo announced receipt of a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling work for APVO451, a trispecific immunotherapy candidate. This is a material operational and strategic milestone—the grant provides external validation of the program, funds advancement toward development candidate selection and IND-enabling studies, and reflects progress on a stated strategic pipeline priority. While not a traditional M\u0026A, financing, or governance event, the grant materially advances the company's clinical development timeline and demonstrates external recognition of its scientific approach, making it operationally significant to investors assessing pipeline progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:21:15.748554+00:00","company_name":"Aptevo Therapeutics Inc.","ticker":"APVO","filing_date":"2026-06-30"}]}